BPC-157
Body Protection Compound 157
The “Wolverine” healing signal — a 15-amino-acid fragment of a gut protein, studied in animals for driving blood flow to injured tissue.
What it is
Drives blood flow to injured tendon, ligament, and gut tissue. People run it for nagging joint and tendon injuries and for gut issues.
It’s acid-resistant — derived from a protein in gastric juice — which makes it one of the few peptides with a usable oral form. In practice the community treats oral as gut-specific: good for digestive issues, but with limited whole-body absorption. For a tendon, joint, or anything systemic, people inject.
Mechanism
Promotes angiogenesis (new blood-vessel growth toward damaged tissue) via VEGF and nitric oxide, and upregulates growth-hormone receptors at injury sites — it doesn’t raise growth hormone itself, it adds more docking sites where the damage is. The effect appears injury-signal-dependent: it acts where there’s damage, not systemically in healthy tissue.
Step 1 · the problem
It starts with an injury.
You tweak your lower back. Deep in the tissue, fibers are torn and inflamed — and tendons and ligaments barely have a blood supply to begin with. Less blood means fewer repair materials reach the damage, which is why these injuries nag for months.
Step 2 · the dose
You inject BPC-157.
It enters the bloodstream and circulates through the whole body. On its own it doesn’t force anything to happen — it’s a signal, looking for somewhere to act.
Step 3 · it finds the damage
It only switches on where you’re hurt.
Healthy tissue ignores it. Damaged tissue is giving off distress signals, and that’s what BPC responds to — so the effect concentrates at the injury instead of spreading everywhere.
Step 4 · the call goes out
It raises a flag called VEGF.
VEGF is your body’s “build blood vessels here” signal — think of it as a flare fired over the injury. The more flares, the stronger the order to grow a fresh supply line toward the damage.
Step 5 · new vessels grow in
Blood vessels sprout toward the injury.
Answering the VEGF call, tiny new capillaries branch out and reach into the damaged tissue. This is angiogenesis — literally growing new plumbing where there wasn’t enough before.
Step 6 · open the pipes
The vessels widen and blood floods in.
BPC also triggers nitric oxide, which relaxes and widens vessels. New roads, now opened wide — oxygen, nutrients, and repair cells pour into the site far faster than before.
Step 7 · more catchers
It adds extra docking ports for repair signals.
BPC doesn’t raise growth hormone. It adds more GH receptors right at the injury — more “catcher’s mitts” so the growth hormone already in your blood can dock and drive repair exactly where it’s needed.
The result
Supply restored. The tissue rebuilds.
With blood flow re-established and repair signals concentrated at the damage, the tissue finally has what it needs to heal. This is why people reach for BPC-157 on stubborn tendon, ligament, and joint injuries.
Mechanism shown is animal-model and theoretical — no human trials confirm it in people.
Standard dose
| Standard dose | 250–500 mcg / daycommunity |
|---|---|
| Route | SubQ or IM — redistributes through the blood and homes to damaged tissue, so it needn’t go right at the injurycommunity |
| Cycle | 4–8 weeks, then a break — run it till healedcommunity |
Reconstitution calculator
U-100 · 100u = 1 mL= 200 units
Set the vial size and water to match your product — amounts vary by supplier. This is unit-conversion math, not medical advice or a dosing recommendation.
Pushing higher— going beyond the standard doseanimal-only
Side effects & cautions
Generally well-tolerated in community use — where side effects show up they’re usually mild and temporary (nausea, dizziness, fatigue). The biggest and most-raised caution is a theoretical cancer risk: it builds blood vessels through the same VEGF/angiogenesis pathway tumors use to grow, so people avoid it with any history of — or undiagnosed — cancer. It’s animal-only, but it’s the reason dose × duration matters. The other loud community theme is sourcing: the market is unregulated and counterfeits and under-dosed vials are common — insist on a certificate of analysis or third-party test before running anything. Anecdotal, unverified reports: dopamine blunting and spider angiomas.
Stacking
The classic pairing is TB-500 — BPC daily plus TB-500 once or twice a week. TB-500 is long-acting and systemic, so you don’t match them pin-for-pin. Same-day injection is fine; no spacing needed.
Evidence & sources
No completed human RCT. The evidence people rely on is rodent tendon and gut research plus small, uncontrolled pilots — two human trials are only now registered.
- Novinšćak T et al. (2008)Animal / in-vitroBPC-157 promotes healing of a transected rat musclerat muscle-injury modelPMID 18668315 ↗
- Vasireddi N et al. (2025)ReviewBPC-157: a review of the preclinical and emerging evidencereviewPMID 40756949 ↗
- ClinicalTrials.gov (2024)Trial registryRegistered BPC-157 human trialClinicalTrials.govNCT02637284 ↗
- ClinicalTrials.gov (2025)Trial registryRegistered BPC-157 human trialClinicalTrials.govNCT07437547 ↗